MLN1202, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. MLN1202 fully met the primary endpoint in Phase II clinical study of patients at high risk for atherosclerosis

For more information about MLN1202 clinical trials, patients and physicians can contact the Millennium Call Center at (800) 589-9005.  Information about ongoing clinical research studies may also be found at http://www.clinicaltrials.gov.